FDA Finalizes Digital Health Technology Guidance Reshaping Remote Data Acquisition in Clinical Trials

Clinical trial design teams integrating wearables, continuous glucose monitors, or connected sensors into study protocols now have a binding regulatory framework to work against: FDA's final guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations establishes the agency's expectations for DHT deployment across drug and biological product development programs.

The guidance closes a gap that has widened since FDA opened a public docket in 2015 to gather stakeholder input on emerging technologies in clinical research. A draft followed in 2021; the final version reflects nearly a decade of agency deliberation, public comment, and legislative mandate. Notably, both the most recent Prescription Drug and Medical Device User Fee Acts and the Food and Drug Omnibus Reform Act of 2022 (FDORA) included explicit DHT-related commitments, directing FDA to publish guidance and develop a framework for DHT use in drug and biological product development.

For regulatory affairs leads preparing submissions that incorporate DHT-derived endpoints, the structural context matters. FDA's Digital Health Center of Excellence, established in 2020, sits alongside a newly formed CDER DHT Steering Committee tasked with ensuring consistent review of drug submissions containing DHT-generated data. Submissions that rely on remotely acquired data from consumer-grade or clinical-grade devices will be evaluated against the principles this committee is now operationalizing.

The operational read for clinical operations and data integrity teams is direct. DHTs as defined in the guidance encompass computing platforms, connectivity software, and sensors, ranging from fitness trackers and wearable blood pressure monitors to continuous glucose monitors. Each device category carries distinct data capture characteristics, and the guidance addresses how those characteristics map to evidentiary standards in clinical investigations. The potential to reduce in-office visit burden while maintaining continuous monitoring introduces both efficiency gains and new data governance obligations under existing 21 CFR Part 11 electronic records requirements.

Equity and access considerations are also embedded in the agency's rationale. FDA notes that DHTs can extend trial participation to populations previously excluded by geography or mobility constraints, a factor that will increasingly surface in diversity action plan reviews under FDORA.

Protocol teams and QA directors should expect CDER's DHT Steering Committee review activity to serve as an early indicator of how DHT-derived data packages will be assessed at submission, with the committee's consistency mandate directly influencing what constitutes adequate validation and data integrity documentation for remotely acquired endpoints.

Source: FDA Guidance Recap Podcast, Office of Medical Policy and Digital Health Center of Excellence, via FDA.gov Drugs RSS Feed, June 23, 2026.